CD46 and prostate carcinoma: For example, a report profiling tumor tissues in microarrays determined that more than 35% of patients with colon/prostate carcinoma assessed demonstrated CD46 upregulation, while in other types of cancers (e.g., lung, brain, lymphoma) less than 11% of tissue samples showed increased CD46 expression (74).